More than 31 million equity shares, representing 12.89 per cent equity of the pharmaceutical company, had changed hands on the NSE till 02:08 PM.
An industry expert pointed out that Chinese companies typically resort to predatory pricing whenever API production increases in India
The decision to enter the European market comes at a time when the global pharmaceutical landscape is undergoing changes
Total revenue stood at Rs 4,567 crore in Q1 FY25 as against Rs 3,516 crore in Q1 FY24
The company also announced that it will work together with the United States Food and Drug Administration (USFDA) to launch the biosimilar rituximab in the US
This will be the company's largest GCC in the world. This is a monumental addition by the company, joining other global giants like Hitachi Energy in establishing their biggest GCCs in Chennai
Sun Pharma failed to adequately clean and maintain equipment used for drug manufacturing at its Dadra-based manufacturing plant, as per the US Food and Drug Administration (USFDA). In a warning letter issued to company's Managing Director Dilip Shanghvi on June 18, the US health regulator stated it inspected the plant in the Union Territory of Dadra and Nagar Haveli and Daman and Diu from December 4-15, 2023. "Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitise and/or sterilise equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements," the USFDA said. The warning letter summarises significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals at the facility, it stated. USFDA further noted that the company's investigations
The USFDA categorised 13 per cent (19 out of 145 inspections) of Indian facilities as 'Official Action Indication'(OAI), which is lower than the global average of 15 per cent OAIs
A fire ripped through a garment factory here and spread to an adjoining pharmaceutical factory, prompting a major relief operation that lasted for more than eight hours and utilised services of over two dozen water tenders, officials said on Saturday. Chief Fire Officer (CFO) Pradeep Kumar said no one was injured in the incident that took place in B-Block of Sector 67. The fire service unit's control room received an alert call about the fire at 12 noon, he said. "We immediately sent eight vehicles to the spot but found that it was a major fire, which had spread from the garment factory to the adjoining pharmaceutical factory. This pharma factory was shut for the past two years but the items which were stocked inside caught the fire and intensified the blaze," Kumar said. "We had to deploy 28 vehicles and by 8.30 pm we were able to completely extinguish the fire. Fortunately, there was no injury to any person and no loss of life in the incident," the CFO said. Kumar said additiona
Companies must commit that they comply with a code against unethical marketing of drugs
The approval for the generic version of Lanreotide Acetate is in line with Cipla's growth strategy in the complex product segment and will strengthen Cipla's position in the US market.
Glenmark Pharmaceuticals Ltd on Friday said it has received final approval from the US health regulator for its generic brimonidine tartrate and timolol maleate ophthalmic solution indicated in the treatment increased pressure in the eye caused by glaucoma or other conditions. The final approval by the US Food & Drug Administration (USFDA) is for brimonidine tartrate and timolol maleate ophthalmic solution of strength 0.2 per cent/0.5 per cent, Glenmark said in a statement. The company's brimonidine tartrate and timolol maleate ophthalmic solution, 0.2 per cent/0.5 per cent has been determined by the USFDA to be bioequivalent and therapeutically equivalent to Combigan ophthalmic solution, 0.2 per cent/0.5 per cent of AbbVie, Inc, it added. The solution will be distributed in the US by Glenmark Pharmaceuticals Inc, USA, it added. Combigan ophthalmic solution, 0.2 per cent/0.5 per cent achieved annual sales of approximately USD 290 million, the company said citing IQVIATM sales data
The drug maker was reportedly interested in buying private equity (PE) firm Advent International's stake in Mumbai-based biopharma firm Bharat Serums and Vaccines (BSV)
It is estimated that more than 120 million people are living with chronic kidney disease in China
Peak XV Partners (formerly Sequoia India) has been invested in La Renon since 2015, with A91 Emerging Fund joining in 2021
MNC's like AstraZeneca's have also collaborated with Mankind Pharma to distribute asthma medication in India further highlights this trend's reach across therapeutic areas
An analysis by market research firm Pharmarack showed how such flagship brands have posted strong growth CAGR in the last five years, with some even doubling sales
A search conducted by Pharmarack showed that brands of any company, labelled under their mother brands, were observed to enjoy greater market share among their peers
With this agreement, India will become the first global territory where Centhaquin (Lyfaquin) is being launched immediately, according to the company
Collaboration aligns with Sanofi's growth strategy in India, named 'India for India', aims to accelerate growth across its pharmaceuticals, specialty care, consumer healthcare, and vaccines business